Development of predictive pharmacokinetic simulation models for drug discovery

被引:73
作者
Norris, DA
Leesman, GD
Sinko, PJ
Grass, GM
机构
[1] Trega Biosci, San Diego, CA 92121 USA
[2] Rutgers State Univ, Coll Pharm, Piscataway, NJ 08854 USA
关键词
ganciclovir; simulation models; bioavailability; humans; dogs;
D O I
10.1016/S0168-3659(99)00232-1
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
As discovery chemistry produces increased numbers of potential drug compounds, the use of ADME (absorption. distribution, metabolism, and excretion) propel-ties is becoming increasingly important in the drug selection and promotion process. A computer simulation model has been developed and validated to predict ADME outcomes, such as rate of absorption, extent of absorption, etc. using a limited number of in vitro data inputs. The oral bioavailability of ganciclovir in dogs and humans was simulated using a physiologically based model that utilized many biopharmaceutically relevant parameters, such as the concentration of ganciclovir in the duodenum, jejunum, ileum, and colon at various dose levels and solubility values. The simulations were run and compared to dog and human in vivo data. The simulation results demonstrated that the low bioavailability of ganciclovir is limited by compound solubility rather than permeability due to partitioning as previously speculated. This technology provides a breakthrough in in silico prediction of absorption and with its continued development and improvement, will aid drug discovery and development scientists to produce better pharmaceutical products. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:55 / 62
页数:8
相关论文
共 29 条
[1]   ESTIMATING HUMAN ORAL FRACTION DOSE ABSORBED - A CORRELATION USING RAT INTESTINAL-MEMBRANE PERMEABILITY FOR PASSIVE AND CARRIER-MEDIATED COMPOUNDS [J].
AMIDON, GL ;
SINKO, PJ ;
FLEISHER, D .
PHARMACEUTICAL RESEARCH, 1988, 5 (10) :651-654
[2]   A THEORETICAL BASIS FOR A BIOPHARMACEUTIC DRUG CLASSIFICATION - THE CORRELATION OF IN-VITRO DRUG PRODUCT DISSOLUTION AND IN-VIVO BIOAVAILABILITY [J].
AMIDON, GL ;
LENNERNAS, H ;
SHAH, VP ;
CRISON, JR .
PHARMACEUTICAL RESEARCH, 1995, 12 (03) :413-420
[3]   GANCICLOVIR ABSOLUTE BIOAVAILABILITY AND STEADY-STATE PHARMACOKINETICS AFTER ORAL-ADMINISTRATION OF 2 3000-MG/D DOSING REGIMENS IN HUMAN IMMUNODEFICIENCY VIRUS-SEROPOSITIVE AND CYTOMEGALOVIRUS-SEROPOSITIVE PATIENTS [J].
ANDERSON, RD ;
GRIFFY, KG ;
JUNG, D ;
DORR, A ;
HULSE, JD ;
SMITH, RB .
CLINICAL THERAPEUTICS, 1995, 17 (03) :425-432
[4]  
ARTURSSON P, 1991, BIOCHEM BIOPH RES CO, V175, P80
[5]   SELECTION OF A DERIVATIVE OF THE ANTIVIRAL AGENT 9-[(1,3-DIHYDROXY-2-PROPOXY)-METHYL]GUANINE (DHPG) WITH IMPROVED ORAL ABSORPTION [J].
BENJAMIN, EJ ;
FIRESTONE, BA ;
BERGSTROM, R ;
FASS, M ;
MASSEY, I ;
TSINA, I ;
LIN, YYT .
PHARMACEUTICAL RESEARCH, 1987, 4 (02) :120-125
[6]  
Budavari S., 1996, MERCK INDEX, V12th
[7]   MIXING-TANK MODEL FOR PREDICTING DISSOLUTION RATE CONTROL OF ORAL ABSORPTION [J].
DRESSMAN, JB ;
FLEISHER, D .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1986, 75 (02) :109-116
[8]   ABSORPTION POTENTIAL - ESTIMATING THE FRACTION ABSORBED FOR ORALLY-ADMINISTERED COMPOUNDS [J].
DRESSMAN, JB ;
AMIDON, GL ;
FLEISHER, D .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1985, 74 (05) :588-589
[9]   Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms [J].
Dressman, JB ;
Amidon, GL ;
Reppas, C ;
Shah, VP .
PHARMACEUTICAL RESEARCH, 1998, 15 (01) :11-22
[10]  
Dunne A, 1999, STAT MED, V18, P1865, DOI 10.1002/(SICI)1097-0258(19990730)18:14<1865::AID-SIM223>3.0.CO